

Table 2

Recent phase III studies in metastatic prostate cancer

Agent	Patient population	Method of action	Trial	Year of publication	Median survival benefit	Additional benefit
Docetaxel ¹²	HSPC and high volume disease*	Chemotherapy	CHAARTED	ASCO abstract 2014	17 months	Improved QOL
Abiraterone ¹³	CRPC (pre-docetaxel)	AR targeted	COA-AA-302	2013	4.4 months	Reduced pain
Enzalutamide ¹⁴	CRPC (pre-docetaxel)	AR targeted	PREVAIL	2014	2.2 months	NA
Alpharadin ¹⁷	CRPC	Radioisotope	ALSYMPCA	2013	3.6 months	Reduced pain

AR = androgen receptor; HSPC = hormone sensitive prostate cancer; CRPC = castrate resistant prostate cancer; * high volume disease is defined as the presence of visceral metastases and/or 4 or more bone metastases with one outside the axial skeleton